A non-nucleotide agonist that binds covalently to cysteine residues of STING

DOI Web Site Web Site PubMed 42 References
  • Matsumoto Kentaro
    Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University
  • Ni Shenwei
    Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo
  • Arai Hiroyuki
    Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo
  • Toyama Takashi
    Laboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences, Tohoku University
  • Saito Yoshiro
    Laboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences, Tohoku University
  • Suzuki Takehiro
    Biomolecular Characterization Unit, Technology Platform Division, RIKEN Center for Sustainable Resource Science
  • Dohmae Naoshi
    Biomolecular Characterization Unit, Technology Platform Division, RIKEN Center for Sustainable Resource Science
  • Mukai Kojiro
    Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University
  • Taguchi Tomohiko
    Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University

Search this article

Description

<p>Stimulator of interferon genes (STING) is an ER-localized transmembrane protein and the receptor for 2',3'-cyclic guanosine monophosphate–adenosine monophosphate (cGAMP), which is a second messenger produced by cGAMP synthase (cGAS), a cytosolic double-stranded DNA sensor. The cGAS-STING pathway plays a critical role in the innate immune response to infection of a variety of DNA pathogens through the induction of the type I interferons. Pharmacological activation of STING is a promising therapeutic strategy for cancer, thus the development of potent and selective STING agonists has been pursued. Here we report that mouse STING can be activated by phenylarsine oxide (PAO), a membrane permeable trivalent arsenic compound that preferentially reacts with thiol group of cysteine residue (Cys). The activation of STING with PAO does not require cGAS or cGAMP. Mass spectrometric analysis of the peptides generated by trypsin and chymotrypsin digestion of STING identifies several PAO adducts, suggesting that PAO covalently binds to STING. Screening of STING variants with single Cys to serine residues (Ser) reveals that Cys88 and Cys291 are critical to the response to PAO. STING activation with PAO, as with cGAMP, requires the ER-to-Golgi traffic and palmitoylation of STING. Our results identify a non-nucleotide STING agonist that does not target the cGAMP-binding pocket, and demonstrate that Cys of STING can be a novel target for the development of STING agonist.</p><p>Key words: STING agonist, cysteine modification, innate immunity, phenylarsine oxide</p>

Journal

References(42)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top